Stockscreener 앱 받기
2.53
1.61%
0.04
시장 영업 전:
2.95
0.42
+16.60%
전일 마감가:
$2.49
열려 있는:
$2.47
하루 거래량:
171.18K
Relative Volume:
1.12
시가총액:
$77.38M
수익:
-
순이익/손실:
$-13.08M
주가수익비율:
-5.7292
EPS:
-0.4416
순현금흐름:
-
1주 성능:
-2.69%
1개월 성능:
-35.95%
6개월 성능:
-47.84%
1년 성능:
-65.20%
1일 변동 폭
$2.44
$2.59
1주일 범위
$2.3536
$2.79
52주 변동 폭
$2.3536
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.53 | 77.38M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
TELO stock touches 52-week low at $2.35 amid market challenges - Investing.com
TELO stock touches 52-week low at $2.46 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.46 amid market challenges - Investing.com
Corebridge Financial Inc. Has $40,000 Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Comparing Telomir Pharmaceuticals (TELO) and The Competition - Defense World
TELO stock touches 52-week low at $2.59 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.59 amid market challenges - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN
SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald
Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener
Telomir-1 shows promise in cancer and chemotherapy study - Investing.com
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India
Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga
Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World
Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa
Telomir-1 shows promise in reversing cell aging - Investing.com India
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune
Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports key preclinical success - Investing.com India
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN
Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times
Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com
Telomir reports stabilization of silver forms for medical use - Investing.com
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
2.03%
자본화:
|
볼륨(24시간):